Hyperkalemia
Conditions
Interventions
investigational material(s)
Generic name etc : Sodium Zirconium Cyclosilicate
INN of investigational material : -
Therapeutic category code : 219 Other cardiovascular agents
Dosage and Administration
Sponsors
AstraZeneca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Provision of informed consent prior to any study specific procedures. - Patients aged 18 or more. For patients aged <20 years, a written informed consent should be obtained from the patient and his or her legally acceptable representative. - Two consecutive i-STAT potassium values, measured 60-minutes (+- 15 minutes) apart, both 5.1mmol/L or more and measured within 1 day before the first dose of ZS on Correction Phase Study Day 1. - Patients who are on peritoneal dialysis (PD) can be enrolled if their SK level is 5.5 or more and less than 6.5mmol/L in two consecutive i-STAT potassium evaluation at least 24 hours apart before Day 1 (in each evaluation, two i-STAT potassium measurements at least 1 hour apart are required). i-STAT potassium measurement should be performed in the morning before breakfast and in the evening before dinner in PD patients on continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD), respectively. - Women of childbearing potential must be using 2 forms of medically acceptable contraception (at least 1 barrier method) and have a negative pregnancy test within 1 day prior to the first dose of ZS on Correction Phase Study Day 1. Women who are surgically sterile or those who are postmenopausal for at least 1 year are not considered to be of childbearing potential.
Exclusion criteria
Exclusion criteria: - Patients treated with lactulose, rifaxan (rifaximin), or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of ZS. - Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene sulfonate [SPS; e.g. Kayexalate] or calcium polystyrene sulfonate [CPS]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug. Washout of SPS and CPS for 7 days (or longer) prior to the first dose of ZS is allowed, if termination of CPS or SPS is judged to be clinically acceptable by the investigator. Documented informed consent has to be obtained prior to the washout. - Patients with a life expectancy of less than 12 months - Female patients who are pregnant, lactating, or planning to become pregnant - Patients who have an active or history of diabetic ketoacidosis - Known hypersensitivity or previous anaphylaxis to ZS or to components thereof - Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry. - Patients with cardiac arrhythmias that require immediate treatment - Hemodialysis patients (including those who are on both PD and hemodialysis [HD]) - Patients who have been on PD less than 6 months or more than 6 months with a history of hypokalemia within 6 months before Correction Phase Day 1 - Documented Glomerular Filtration Rate (GFR) < 15mL/min within 90 days prior to study entry. (Non peritoneal dialysis (PD) patients only) - If patients joined ZS study in the past, the patients cannot join this study within the last 30 days of the last study drug administration day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety - | — |
Secondary
| Measure | Time frame |
|---|---|
| safety efficacy exploratory - | — |
Countries
Japan
Outcome results
None listed